Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.12T
Market cap1.12T
Price-Earnings ratio
42.09
Price-Earnings ratio42.09
Dividend yield
0.55%
Dividend yield0.55%
Average volume
2.32M
Average volume2.32M
High today
$1,189.59
High today$1,189.59
Low today
$1,142.01
Low today$1,142.01
Open price
$1,144.00
Open price$1,144.00
Volume
1.91M
Volume1.91M
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

As of today, Eli Lilly(LLY) shares are valued at $1,185.50. The company's market cap stands at 1.12T, with a P/E ratio of 42.09 and a dividend yield of 0.55%.

During the trading session on 2026-07-23, Eli Lilly(LLY) shares reached a daily high of $1,189.59 and a low of $1,142.01. At a current price of $1,185.50, the stock is +3.8% higher than the low and still -0.3% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 1.91M, versus its average volume of 2.32M.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

LLY News

CNBC 5h
BMO's Evan Seigerman: I prefer Eli Lilly over Novo Nordisk in the obesity trade - CNBC

...

BMO's Evan Seigerman: I prefer Eli Lilly over Novo Nordisk in the obesity trade - CNBC
Nasdaq 5h
S&P 500 Analyst Moves: LLY

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Eli Lilly is now the #61 analyst pick...

S&P 500 Analyst Moves: LLY
Nasdaq 5h
Eli Lilly Achieves #19 Analyst Rank, Surpassing Live Nation Entertainment

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Eli Lilly (Symbol: LLY) has taken over the #19 spot...

Eli Lilly Achieves #19 Analyst Rank, Surpassing Live Nation Entertainment

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More LLY News

Investor's Business Daily 6h
There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders

Technology There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders Licensing Eli Lilly (LLY) said Thursday it will delay filing for...

There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders
Barron's 8h
Lilly Stock Is Rising on Plan to Seek Approval for Newest Weight-Loss Drug in 2027

Biotech and Pharma Lilly Stock Is Rising on Plan to Seek Approval for Newest Weight-Loss Drug in 2027 In this article SPX Eli Lilly’s weight loss drugs have cat...

Lilly Stock Is Rising on Plan to Seek Approval for Newest Weight-Loss Drug in 2027
TipRanks 10h
Eli Lilly Targets 2027 for Approval of Its Next-Generation Obesity Drug

Pharmaceutical giant Eli Lilly (LLY) says it is targeting the first quarter of 2027 for approval of its next-generation weight-loss drug. Claim 55% Off TipRanks...

Simply Wall St 11h
Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors

The race to treat obesity and diabetes is shifting again after Eli Lilly pushed back approval plans for its next-generation obesity drug, retatrutide, to Q1 202...

Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors
Nasdaq 11h
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.

Key Points Eli Lilly is going to buy a psychedelic drug biotech called AtaiBeckley. It'll be getting a handful of mid-stage clinical programs for behavioral h...

Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.
Benzinga 11h
Eli Lilly Says Retatrutide Shows Cardiovascular, Diabetic Benefits

The studies demonstrated significant weight reduction in adult patients managing obesity alongside severe complications, including type 2 diabetes and establish...

Eli Lilly Says Retatrutide Shows Cardiovascular, Diabetic Benefits
Seeking Alpha 13h
Lilly to seek FDA nod for next-gen weight loss drug early next year after latest trial wins

Eli Lilly (LLY) on Thursday announced plans to seek FDA approval for its next-gen weight-loss therapy, retatrutide, early next year after the triple hormone rec...

Lilly to seek FDA nod for next-gen weight loss drug early next year after latest trial wins

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.